<DOC>
	<DOCNO>NCT00673062</DOCNO>
	<brief_summary>This study evaluate effectiveness new drug congestion subject seasonal allergic rhinitis . This effect compare placebo decongestant , pseudoephedrine .</brief_summary>
	<brief_title>Study Effect SCH 900538 Congestion Subjects With Seasonal Allergic Rhinitis ( Study P05031 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<criteria>Subjects must 18 65 year age , either sex , race . Subjects must history SAR due ragweed last two consecutive ragweed season . Subjects must skintest positive ragweed pollen allergen use Environmental Exposure Unit ( pollen chamber Screening Visit within 12 month prior Screening Visit . Subjects must develop predefined severity allergy symptom within 90minute enter pollen chamber pollen challenge Priming visit ( Visit 2 ) , prior dosing ( Visit 3 ) , order qualify study . Female subject childbearing potential must negative serum pregnancy test Screening negative urine pregnancy test prior randomization Treatment Visit . Female subject female partner male subject must use acceptable form birth control study . Blood pressure pulse rate must within normal range . Subjects upper low respiratory tract infection within approximately 28 day ( 4 week ) Priming ( Visit 2 ) thereafter . Subjects dependence upon nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid , opinion investigator . Subjects clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study . Subjects use investigational drug , include placebo , within 30 day Screening duration stud , participate clinical study . Subjects history rhinitis medicamentosa . Subjects history anaphylaxis severe serious reaction skin test . Subjects medically treat following condition : narrowangle glaucoma , increase intraocular pressure , urinary retention , hypertension , severe coronary artery disease , ischemic heart disease , diabetes mellitus , hyperthyroidism , renal impairment , prostatic hypertrophy ; current treatment monoamine oxidase ( MAO ) inhibitor . Subjects history positive test , symptomatic , HIV , TB ( due vaccination ) , hepatitis B ( due vaccination ) hepatitis C. Subjects asthma require medication occasional ( &lt; =3 us per week ) use inhale shortacting b2 agonist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>